Awakn Partners With University Of Nottingham For Preclinical Testing Of Psychoactive Therapy
Investors Back Awakn's Psychedelic Therapies, As Company Doubles Private Placement To $2M
CSE Bulletin: Reinstatement - Awakn Life Sciences Corp. (AWKN)
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Awakn Life Sciences Inks Licensing Partnership Deal With Oklahoma-based Clinic
Canadian Securities Exchange Reports February 2024 Performance Figures
Canadian Securities Exchange Welcomes Listing of Awakn Life Sciences Corp
CSE Bulletin: New Listing - Awakn Life Sciences Corp. (AWKN)
Awakn Life Sciences Announces Conditional Approval of CSE Listing
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
U.K.'s Prof. David Nutt Ranked World's Top Psychopharmacologist: More On His Contributions & Advocacy
No Data
No Data